ComGenex takes name of new owner
Hungarian drug discovery service company ComGenex Rt announced on Wednesday it has taken the name of its new parent company Albany Molecular Research (AMRI) and it will go on as AMRI Hungary Zrt.
AMRI signed the contract to buy ComGenex at the end of January 2006, and closed the transaction on March 1, paying $11 million for the company, according to industry insiders. In its first-quarter report, AMRI said ComGenex contributed $500,000 to its first-quarter contract revenue from discovery services. ComGenex had revenue of $8.5 million in 2005 and targeted an increase of at least 10% this year. AMRI had total revenue of $36.2 million in Q1 2006, including $8.4 million contract revenue from discovery services.
AMRI is a global drug discovery company that provides chemistry services to pharmaceutical and biotechnology companies and conducts its own proprietary R&D programs. Its shares are traded on the NASDAQ.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.